Navigation Links
Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months
Date:10/8/2008

continue development of a pandemic influenza vaccine candidate.

"Through independent and collaborative research, we have demonstrated Vaxfectin(R)'s ability as an adjuvant to increase antibody and/or T-cell responses with DNA vaccines and with protein- and peptide-based vaccines," said Dr. Rolland. "We are advancing with development of our own Vaxfectin(R)-formulated product candidates and are exploring opportunities with potential collaborators and commercial partners for development of additional infectious disease and cancer applications for this novel adjuvant."

About Vical

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at http://www.vical.com.

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about the results of the company's Vaxfectin(R)-formulated H5N1 influenza DNA vaccine Phase
'/>"/>

SOURCE Vical Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
2. Multiple NIH Phase 2 HIV Vaccine Trials Using Vicals Technology Produce Encouraging Results
3. Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza
4. Spine Institute of Louisiana Offers Cervical Spine Motion Preservation as an Alternative to Fusion Surgery
5. Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations
6. The First Annual Cervical Cancer/HPV Conference Tackles Controversial Vaccine Issues and Encourages Advocacy
7. Vical Demonstrates Dose-sparing of Protein-based H5N1 Influenza Vaccine With Vaxfectin(TM) Adjuvant
8. New Study Shows Listeria Vaccine for Cervical Cancer Found Safe
9. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
10. Vical Receives Payment from AnGes MG for Allovectin-7(R) Phase 3 Pivotal Trial
11. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly larger ... painless for patients to self-inject prescription drugs in the large ... cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to $220B by 2018, according to analysts.   Many of these ...
(Date:1/14/2014)... 2014 Dynamic Healthcare Services, Inc. ("DHS"), a portfolio company ... Progressive Home Medical Equipment, Inc. ("Progressive") of Clarion, ... the acquisition were not disclosed. Progressive is ... wide range of sleep, mobility, and respiratory products to customers ...
(Date:1/14/2014)...   Oligomerix, Inc. , a privately held company pioneering ... (AD) and related neurodegenerative disorders, announced today the relocation ... as of January 15, 2014 and expanded ... Medical College. Oligomerix, which is focused on ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... Inc. (OTCBB: ECTE), a company developing its needle-free ... continuous glucose monitoring system and its Prelude™ SkinPrep ... Patrick T. Mooney, M.D., CEO, President and Chairman ... at the Jefferies 2011 Global Healthcare Conference. ...
... CHENGDU, China, June 3, 2011 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical ... pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized ... announced that the Board of Directors has reinstated the ... to 3 million TPI,s common stock on the open ...
Cached Medicine Technology:TPI Board Reinstates Stock Repurchase Program 2
(Date:4/17/2014)... cause of neuronal death in Parkinson,s disease is still ... be mistaken for foreign invaders and killed by the ... diseases like type I diabetes, celiac disease, and multiple ... April 16, 2014, in Nature Communications . , ... Parkinson,s disease; but if true, it could lead to ...
(Date:4/17/2014)... team led by researchers at UC Davis has shown ... key role in cell division, also boosts the mitochondrial ... time the complex has been shown to perform both ... excellent target to control cellular energy production, potentially advancing ... online today in the journal Developmental Cell . ...
(Date:4/17/2014)... April 17, 2014 Meaningful long-term survival ... cancer of the abdomen when treated with cytoreductive ... to a first-of-its-size analysis by physicians at Wake ... has the largest reported, single-center experience with cytoreductive ... Levine, M.D., and analysis of 20 years, worth ...
(Date:4/17/2014)... 2014 Giving patients adrenaline after they suffer a cardiac ... prospects of surviving long-term, according to new research conducted ... patients who have a cardiac arrest get adrenaline, which ... for decades," said Dr. Steve Lin, an emergency physician ... advances in medical treatment, long-term survival rates of patients ...
(Date:4/16/2014)... The Translational Genomics Research Institute (TGen) recently honored two ... their support of TGen,s research into brain, colon and ... Scottsdale. , Catherine Ivy, Founder and President of The ... McCain Leadership Award, named for U.S. Sen. John McCain ...
Breaking Medicine News(10 mins):Health News:Is Parkinson's an autoimmune disease? 2Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:20 years of data shows treatment technique improvement for advanced abdominal cancer 2Health News:Adrenaline does little to increase patient's survival after cardiac arrest 2Health News:TGen honors Catherine Ivy and Craig Jackson with Leadership; Collaborative Spirit awards 2
... Drug Information Association (DIA), in collaboration with FDA, the Medical ... Radiopharmaceuticals (CORAR), PhRMA, and the American Medical Informatics Association (AMIA), ... Uses of Medical Imaging in the Development of New Biopharmaceutical ... ...
... is a break-through Nitinol wire product which features an exclusive ... acid solutions which cause embrittlement. The resulting NitiBrite™ ... other known methods. , ... West ...
... Komen for the Cure(R), the,leader of the global ... G. Komen for the Cure Advocacy Alliance, have ... self awareness and the need for,increased access to ... (Logo: http://www.newscom.com/cgi-bin/prnh/20070122/NYM084LOGO ), Komen for the ...
... Companies Will Discuss Recent FDA Advisory Regarding Byetta, ... LLY ) and Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ... 2008 at 5:00 p.m. EDT to discuss the,recent FDA ... Lilly will be Donald Therasse, M.D., vice president of ...
... fail to alert docs to effectiveness of alternative therapies ... slowed the use of antipsychotic drugs in seniors with ... the elderly increased, a finding which suggests that warnings ... say. , Between late 2002 and June 2005, ...
... HCA marked its 40th,anniversary during a special program for ... featured HCA Co-Founder and Chairman Emeritus, Dr. Thomas,Frist, Jr. ... who spoke about,HCA,s founding, mission and tradition of caring ... of Caring" program was a,prelude to HCA,s annual Caring ...
Cached Medicine News:Health News:Shaping Best Practices For Standardized Medical Imaging In Clinical Trials 2Health News:Shaping Best Practices For Standardized Medical Imaging In Clinical Trials 3Health News:NitiBrite™ - Break-through in Nitinol Wire Product for Medical Devices 2Health News:Komen Travels to Democratic Convention in Denver to Raise Awareness of Breast Cancer Issues 2Health News:Lilly and Amylin Set Date and Time for Conference Call 2Health News:Antipsychotic Drug Use Up in Elderly Despite Warnings 2Health News:HCA Celebrates 40th Anniversary 2
... To Manually Dilate A Small Pupil With ... Maximizes Safety By Allowing The Iris Hooks ... To The Plane Of The Anterior Capsule, ... Tears. Pupil Stretching Is Also Maximized, With ...
... To Rest Either Nasally Or Temporally ... Allowing Eyelids To Be Opened From ... Possible Aperture., ,Open And Close With ... To The Globe During Clear Corneal ...
... Designed To Rest Either Nasally Or ... Over, Allowing Eyelids To Be Opened ... Widest Possible Aperture.,Open And Close With ... To The Globe During Clear Corneal ...
... Special Low-profile Hourglass Jaw Design Holds ... A Minimal Incision.,Mirror Polished Blades Keep ... Handle Mechanism Offers Control Over Release ... The Lens From Tilting During Insertion.,Reusable, ...
Medicine Products: